Department of Public Health, Helsinki University, Mannerheimintie 172, FI-00300, Helsinki, Finland.
Department of Orthopedics and Traumatology, Päijät-Häme Central Hospital, Keskussairaalankatu 7, FI-15850, Lahti, Finland.
Osteoporos Int. 2022 Mar;33(3):611-621. doi: 10.1007/s00198-021-06094-z. Epub 2021 Sep 30.
The association between serum 25-hydroxyvitamin D level and post-fracture mortality indicates beneficial relatively high serum 25-hydroxyvitamin D concentrations. A 1-year cohort study on 245 hip fracture patients in Finland indicated the lowest 3-year mortality and highest survival among patients with serum 25-hydroxyvitamin D level of 50-74 nmol/L.
To explore pre-fracture serum 25-hydroxyvitamin D level as a factor associated with post-fracture survival among a cohort of hip fracture patients in Finland.
A prospectively collected cohort of hip fracture patients (n = 245, 70% women) from two hospitals was followed for 3.2 post-hip fracture years. Serum 25-hydroxyvitamin D was measured in admission to the hospital and classified: < 50, 50-74, 75-99, and ≥ 100 nmol/L. Survival was analyzed with a Bayesian multivariate model. Relative survival was explored with the life table method according to serum 25-hydroxyvitamin D. Mortality according to serum 25-hydroxyvitamin D level and to the hospital was calculated.
Mortality in the patients with serum 25-hydroxyvitamin D level of 50-74 nmol/L was significantly lower than in all other patients together at every post-fracture year. The most important factors for survival were age under 85 years; living in an actual/private home; serum 25-hydroxyvitamin D level of 50-74 nmol/L, followed by 75-99 nmol/L; ASA classes 1-2 and 3; and female sex. The mean age of patients with serum 25-hydroxyvitamin D level of 50-99 nmol/L was significantly higher than in other levels. Relative survival was highest in men, women, and patients in hospital B with serum 25-hydroxyvitamin D level of 50-74 nmol.
The highest 3-year survival and the lowest mortality in this cohort appeared in patients with pre-fracture serum 25-hydroxyvitamin D level of 50-74 nmol/L. This result differs from similar studies and is lower than the recommended level of 25-hydroxyvitamin D among hip fracture patients. The results should be examined in future research with larger data.
探讨芬兰髋部骨折患者队列中骨折前血清 25-羟维生素 D 水平与骨折后生存相关的因素。
前瞻性收集来自两家医院的髋部骨折患者队列(n=245,70%为女性),随访 3.2 年。入院时测量血清 25-羟维生素 D,并分类为:<50、50-74、75-99 和≥100nmol/L。采用贝叶斯多变量模型分析生存情况。根据血清 25-羟维生素 D 采用寿命表法探讨相对生存率。根据血清 25-羟维生素 D 水平和医院计算死亡率。
血清 25-羟维生素 D 水平为 50-74nmol/L 的患者在每个骨折后年的死亡率均显著低于其他所有患者。生存的最重要因素是年龄<85 岁;居住在实际/私人住宅;血清 25-羟维生素 D 水平为 50-74nmol/L,其次是 75-99nmol/L;ASA 分级 1-2 和 3;女性。血清 25-羟维生素 D 水平为 50-99nmol/L 的患者平均年龄显著高于其他水平。男性、女性和血清 25-羟维生素 D 水平为 50-74nmol/L 的 B 医院患者的相对生存率最高。
该队列中最高的 3 年生存率和最低的死亡率出现在骨折前血清 25-羟维生素 D 水平为 50-74nmol/L 的患者中。这一结果与类似研究不同,且低于髋部骨折患者推荐的 25-羟维生素 D 水平。应在未来的研究中用更大的数据进行检验。